A study published in the Proceedings of the National Academy of Sciences outlines how the drug acts to disrupt SM protein at key stages in the viral life cycle, and might form the basis of an effective drug to fight Epstein-Barr virus. Current drugs for Epstein-Barr and other viruses in the herpes family are focused on targeting replication of viral DNA, according to the paper.
“We have shown that spironolactone specifically acts to inhibit Epstein-Barr virus SM protein function, which is required for expression of several … Epstein-Barr Virus genes and infectious Epstein-Barr Virus production,” the authors wrote. “The effect of spironolactone parallels the effect of knocking out SM function, which is critical for expression of Epstein-Barr virus.”
More articles on quality:
No food may be better than eating via IV for children in ICU, study suggests
APIC release updated guide to prevent CLABSI
Researchers find patients with heart disease may benefit from omega-3 supplements
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.